首页> 外文期刊>Cardiovascular revascularization medicine: including molecular interventions >Impact of atrial fibrillation in patients with chronic kidney disease undergoing transcatheter aortic valve replacement: Insights of the Healthcare Cost and Utilization Project's National Inpatient Sample
【24h】

Impact of atrial fibrillation in patients with chronic kidney disease undergoing transcatheter aortic valve replacement: Insights of the Healthcare Cost and Utilization Project's National Inpatient Sample

机译:心房颤动对经经沟管主动脉瓣置换的慢性肾病患者的影响:医疗保健成本和利用项目的国家住院样品见解

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background Limited data exists exploring the relationship between varying degrees of chronic kidney disease (CKD) and atrial fibrillation (AF) in patients undergoing transcatheter aortic valve replacement (TAVR). Methods Records were selected from the 2011 to 2012 Healthcare Cost and Utilization Project's National Inpatient Sample for TAVR patients with pre-existing AF and CKD. Demographics, clinical characteristics, and TAVR-related in-hospital adverse events were identified and compared between patients with and without AF and moderate CKD (CKD stage 3–4), and between patients with and without AF and severe CKD (CKD stage 5 or end stage renal disease [ESRD]). Evaluated outcomes included major adverse cardiac and cerebrovascular events (MACCE). Results We identified a total of 293 patients with moderate CKD (stage 3 and higher) that underwent TAVR at selected U.S. hospitals between 2011 and 2012. Among these patients, 112 had a diagnosis of AF and 181 did not have AF. MACCE rates were similar among CKD 3–4 patients with and without AF (10.3% and 9.0% respectively, p=0.74). MACCE rates were similar among CKD 5/ESRD patients with and without AF (20.0% and 16.2% respectively, p=0.74). However, MACCE rates were higher in patients with CKD 5/ESRD compared with CKD 3–4 patients. Multivariate logistic regression analysis did not show that AF was an independent predictor of in-hospital MACCE. Conclusions In a large retrospective analysis of CKD stage 3–4 or CKD 5/ESRD patients undergoing TAVR at selected U.S. hospitals, the presence of AF did not seem to be associated with increased adverse in-hospital events or length of stay. Highlights ? In a large retrospective analysis of 293 with chronic kidney disease stage 3–4 or end stage renal disease on dialysis replacement therapy (stage 5) undergoing TAVR, the presence of atrial fibrillation did not seem to be associated with an increased rate of adverse in-hospital events, stroke or length of stay.
机译:摘要背景:研究经导管主动脉瓣置换术(TAVR)患者不同程度的慢性肾病(CKD)与心房颤动(AF)之间关系的数据有限。方法从2011年至2012年医疗成本和利用项目的全国住院患者样本中选择记录,记录先前存在房颤和CKD的TAVR患者。在患有和不患有AF和中度CKD(CKD 3-4期)的患者之间,以及患有和不患有AF和重度CKD(CKD 5期或终末期肾病[ESRD])的患者之间,确定并比较人口统计学、临床特征和TAVR相关的院内不良事件。评估结果包括重大不良心脑血管事件(MACCE)。结果我们在2011年至2012年间,在选定的美国医院共发现293例中度CKD(3期及以上)患者接受了TAVR治疗。在这些患者中,112例诊断为房颤,181例未诊断为房颤。伴有和不伴有房颤的CKD 3-4患者的MACCE发生率相似(分别为10.3%和9.0%,p=0.74)。伴有和不伴有房颤的CKD 5/ESRD患者的MACCE发生率相似(分别为20.0%和16.2%,p=0.74)。然而,CKD 5/ESRD患者的MACCE发生率高于CKD 3-4患者。多变量逻辑回归分析未显示房颤是院内MACCE的独立预测因子。结论在对在选定的美国医院接受TAVR治疗的CKD 3-4期或CKD 5/ESRD患者进行的大型回顾性分析中,AF的存在似乎与不良住院事件或住院时间的增加无关。亮点?在对293例接受TAVR的慢性肾病3-4期或终末期肾病透析替代治疗(5期)患者进行的大型回顾性分析中,心房颤动的存在似乎与不良住院事件、中风或住院时间的增加无关。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号